Granisetron: Is there a dose-response effect on nausea and vomiting?

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 2, 2003, Pages 89-98

  Minami, Masaru ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

5 HT3 receptor antagonist; Antiemetic; Dose response; Granisetron; Supportive care

Indexed keywords

AZASETRON; CISPLATIN; CYTOTOXIC AGENT; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

CANCER PATIENT; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DISEASE CONTROL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HEADACHE; HEALTH CARE COST; HUMAN; HYPOTENSION; LONG QT SYNDROME; NAUSEA; NONHUMAN; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SEROTONINERGIC TRANSMISSION; VERTIGO; VISUAL IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANISETRON; HUMANS; NAUSEA; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0042377502     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0652-6     Document Type: Review

References (100)

1. Aapro MS, Kirchner V, Terrey JP (1994) The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 69:957
2. Addelman M, Erlichman C, Fine S, Warr D, Murray C (1990) Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 8:337
3. 3 antagonist, in healthy human subjects. Eur J Clin Pharmacol 46:159
4. 3 receptor antagonists and emesis; a pre-clinical review. Pharma Med 13:153
5. Andrews PLR, Davis CJ (1993) The mechanism of emesis induced by anti-cancer therapies. In: Andrews PLR, Sanger GJ (eds) Emesis in anticancer therapy, mechanisms and treatment. Chapman & Hall, London, p 14
6. Andrews PLR, Davis CJ, Bingham S, Davidson HIM, Hawthorn J, Maskell L (1990) The abdominal visceral innervation and the emetic reflex: pathways, pharmacology and plasticity. Can J Physiol Pharmacol 68:325
7. 3 receptor antagonists the same? Eur J Cancer 28A:52
8. Anzemet (dolasetron mesylate) tablets and injection (1999) Prescribing Information. Hoechst Marion Roussel, Kansas City, MO
9. ASHP (1999) ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56:729
10. Balducci L (2001) A practical approach to the older patient. Curr Probl Cancer 25:6
11. Baltzer L, Kris MG, Hinkley L, Pisters K, Lacava PV, Pierri MK, Rigas JR, Grant SC, Gralla R J, Grunberg S, Hahne W (1994) Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae? (abstract 1489). Proc Am Soc Clin Oncol 13:433
12. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Bricker LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969
13. 3) receptor-mediated depolarisation of the rat isolated vagus nerve: modulation by trichloroethanol and related alcohols. Eur J Pharmacol 354:25
14. Bermudez J, Boyle EA, Miner WD, Sanger GJ (1988) The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 58:644
15. 3 receptor antagonists granisetron and azasetron in the conscious ferret. Pharmacometrics 47:21
16. Bleiberg HH, Speilmann M, Falkson G, Romain D (1995) Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose ranging study. Clin Ther 17:38
17. Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557
18. 3 receptor antagonist drugs. In: Dubois A, King GL, Livengood DR (eds) Radiation and the GI tract. CRC Press, Boca Raton, p 37
19. Blower PR (1995) A pharmacologic profile of oral granisetron (Kytril tablets). Semin Oncol 22 [Suppl 10]:3
20. 3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 8:404
21. Blower PR (2003) Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 11:93
22. 3 receptor blockade? Br J Cancer 86:1665
23. Bonhaus DW, Stefanich E, Loury DN, Hsu SA, Eglen RM, Wong EH (1995) Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors. J Neurochem 65:104
24. Bosnjak SM, Neskovic-Konstantinovic ZB, Jovanovic-Micic DJ, Mitrovic LB, Radulovic SS (1996) Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. J Chemother 8:315
25. Bubalo J, Seelig F, Karbowicz S, Maziarz RT (2001) Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Bone Marrow Transplant 7:439
26. 3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 24:45
27. Carmichael J, Phillip PA, Forfar C, Harris AL (1995) An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 37:134
28. Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE (1998) Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs 9:381
29. Carney DN (1994) Chemotherapy induced nausea and vomiting. Ir Med J 87:1323
30. Chin SB, Kucuk O, Peterson R, Ezdinli EZ (1992) Variables contributing to anticipatory nausea and vomiting in cancer chemotherapy. Am J Clin Oncol 15:262
31. 3 receptor antagonist. Br J Clin Pharmacol 25:106
32. Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419
33. Cowan JD, Neidhart J, McClure S, Coltman CA (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a South-West Oncology Group study. J Natl Cancer Inst 83:1077
34. 3 antagonists. Br J Cancer 76:1055
35. de Wit R, van den Berg H, Burghouts J, Nortier J, Slee P, Rodenburg C, Keizer J, Fonteyn M, Verweij J, Wils J (1998) Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 77:1487
36. de Wit R, de Boer AC, Linden GHM, Stoter G, Sparreboom A, Verweij J (2001) Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 85:1099
37. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225
38. Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3:113
39. Du Bois A (1999) Klinik und management der chemotherapie-induzierten emesis. In: Du Bois A, Feyer P, Ortner P (eds) Emesis in der tumortherapie. Ellyott Medizin Verlag, Hamburg, p 40
40. Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, Bertrand D (1993) Chimaeric nicotine-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 366:409
41. 3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum. Res Commun Mol Pathol Pharmacol 104:145
42. Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41:400
43. Flaherty JH, Perry HM, Lynchard GS, Morley JE (2000) Polypharmacy and hospitalization among older home care patients. J Gerontol Med Sci 55:554
44. Fujii Y, Tanaka H (1999) Granisetron reduces post-operative vomiting in children: a dose-ranging study. Eur J Anaesth 16:62
45. Fujii Y, Toyooka H, Tanaka H (1996) Effective dose of granisetron for preventing postoperative emesis in children. Can J Anaesth 43:660
46. 3 receptor antagonists: a review of preclinical and clinical results with ICS 205-930. Cancer Treat Rev 17:301
47. 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer 6:237
48. 4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Arch Pharmacol 347:137
49. 3-receptor antagonists for the treatment of nausea and vomiting - a re-appraisal of their side-effect profile. Oncologist 7:424
50. Gralla RJ (1994) Antiemetic treatment for cancer chemotherapy: problems and progress. Support Cancer Care 2:275
51. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG, for the American Society of Clinical Oncology (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971
52. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189
53. Grote TH, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, Karlan BY, Reeves JA, Potter LL, Benedict CR, Hahne WF (1997) Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am 3:45
54. Hacking A (1992) Oral granisetron - simple and effective: a preliminary report. The Granisetron Study Group. Eur J Cancer 28A [Suppl 1]:S28
55. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163
56. 3-receptor functions by external H-7, a protein kinase inhibitor, in rat sensory neurones. Br J Pharmacol 122:1195
57. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer 29A:1669
58. Kaiser R, Sezer O, Papies A, Bouer S, Schelenz C, Tremblay P, Possinger K, Roots I, Brockmoller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805
59. Kamanabrou D, on behalf of the Granisetron Study Group (1992) Intravenous granisetron - establishing the optimal dose. Eur J Cancer 28A:S6
60. Kytril injection (granisetron hydrochloride) (1999) Prescribing information. SmithKline Beecham Pharmaceuticals, Philadelphia, PA
61. Leclerc JM, Jacobson SJ, Cohn R, Upward J, Murdoch RD (1993) A double-blind dose-ranging study of IV granisetron in children undergoing highly emetogenic chemotherapy (abstract). Proc Am Soc Clin Oncol 12:437
62. Lemerle J, Amaral D, Southall DP, Upward J, Murdoch RD (1991) Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer 27:1081
63. Lindley C, Blower P (2000) Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm 57:1685
64. Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Proto E, Santona MC (1996) Comparison of granisetron, ondansetron and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 77:941
65. 3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep 5:273
66. Marr HE, Davey PT, Boyle EA, Blower PR (1994) Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Pharmacology 48:238
67. Martoni A, Piana E, Strocchi E, Angelelli, Guaraldi M, Zamagni C, Camaggi CM, Pannuti F (1998) Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cisplatinum-induced emesis. Anticancer Res 18:2799
68. Marty M, Kleisbauer J-P, Fournel P, Vergnenegre A, Carles P, Loria-Kanza Y, Simonetta C, de Bruijn KM (1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anticancer Drugs 6:15
69. Mayersohn M (1994) Pharmacokinetics in the elderly. Environ Health Perspect 102 [Suppl 11]:119
70. Minami M, Endo T, Nemoto M, Hamaue N, Hirafuji M, Monma Y, Yajima T, Yoshioka M, Saito H (1995) How do toxic emetic stimuli cause 5-HT release in the gut and brain? In: Raynolds DJM, Andrews PLR, Davis CJ (eds) Serotonin and the scientific basis of anti-emetic therapy. Oxford Clinical Communications, Oxford, p 68
71. Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagomsm. Br J Pharmacol 88:497
72. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204
73. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242
74. Navoban (tropisetron hydrochloride) (1997) Approved product information. Novartis Pharmaceuticals Australia, North Ryde, NSW
75. NCCN (1997) NCCN antiemesis practice guidelines (National Comprehensive Cancer Network, Rockledge, PA). Oncology (Huntingt) 11(11A):57
76. 3 receptors. Neuropharmacology 32:729
77. Palmer R (1994) Efficacy and safety of granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function. Semin Oncol 21:22
78. 3 receptors: focus on alcohols and anaesthetic agents. Trends Pharmacol Sci. 17:95
79. Perez EA (1991) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036
80. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754
81. Riviere A, on behalf of The Granisetron Study Group (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967
82. Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, DiCostanzo F, Donati D, Ballatori E, Tognoni G, Franzosi MG, Favero AD (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5:141
83. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004
84. 3 receptor antagonists (setrons) for chemotherapy-induced emesis. Pharmacoeconomics 18:533
85. Sanwald P, David M, Dow J (1996) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Drug Metab Dispos 24:602
86. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D, de Mulder PHM (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 66:192
87. Sigsgaard T, Herrstedt J, Anderson LJ, Havsteen H, Langer SW, Kjaerbol A-G, Lund H, Kjaer M, Dombernowsky P (1999) Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer 80:412
88. Smith IE (1993) A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol 119:350
89. Soukop M (1994) A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 2:177
90. Terrey J-P, Aapro MS (1996) The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res 8:281
91. Tsavaris N, Kosmas M, Vadiaka CH, Vadiaka M, Kontos A, Katsorida M, Dimitrakopoulos A, Zerai A, Koufos CH (2001) Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. J Exp Clin Cancer Res 20:29
92. Tsuchida Y, Hayashi Y, Asami K, Yamamoto K, Yokoyama J, Mugishima H, Honna T, Mimaya J, Hara F, Sawada T, Matsumura T, Suita S, Sugimoto T, Kaneko M (1999) Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Int J Oncol 14:673
93. Tuladhar BR, Womack MD, Naylor RJ (2000) Pharmacological characterization of the 5-HT receptor-mediated contraction in the mouse isolated ileum. Br J Pharmacol 131:1716
94. 3 antagonist. Eur J Cancer 26 [Suppl 1]:S12
95. van Belle SJ-P, Stamatakis L, Bleiberg H, Cocquyt VFJ, Michel J, de Bruijn KM (1994) Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 5:82
96. 3 receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. Neuropharmacology 36:649
97. van Wijngaarden I, Tulp MT, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 138:301
98. Wei JY (1995) Cardiovascular comorbidity in the older cancer patient. Semin Oncol 22:9
99. Yancik R (1997) Cancer burden in the aged. Cancer 80:1273
100. Zofran injection (ondansetron hydrochloride) (1996) Prescribing information. Glaxo Wellcome, Research Triangle Park, NC